La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Baxter International Gestion
Gestion contrôle des critères 2/4
Le PDG Baxter International's est Joe Almeida, nommé en Jan2016, a un mandat de 8.58 ans. La rémunération annuelle totale est $ 13.79M, composée du salaire de 9.4% et des bonus 90.6%, y compris les actions et options de la société. détient directement 0.11% des actions de la société, d'une valeur de $ 20.59M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 4.5 ans.
Informations clés
Joe Almeida
Directeur général
US$13.8m
Rémunération totale
| Pourcentage du salaire du PDG | 9.4% |
| Durée du mandat du directeur général | 8.6yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 1.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.5yrs |
Mises à jour récentes de la gestion
Recent updates
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07
Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Is Baxter International (NYSE:BAX) Using Too Much Debt?
Apr 03Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 18Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$157m |
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$14m | US$1m | -US$76m |
| Sep 30 2023 | n/a | n/a | US$225m |
| Jun 30 2023 | n/a | n/a | -US$3b |
| Mar 31 2023 | n/a | n/a | -US$3b |
| Dec 31 2022 | US$14m | US$1m | -US$3b |
| Sep 30 2022 | n/a | n/a | -US$3b |
| Jun 30 2022 | n/a | n/a | US$876m |
| Mar 31 2022 | n/a | n/a | US$992m |
| Dec 31 2021 | US$16m | US$1m | US$1b |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | US$16m | US$1m | US$1b |
| Sep 30 2020 | n/a | n/a | US$911m |
| Jun 30 2020 | n/a | n/a | US$924m |
| Mar 31 2020 | n/a | n/a | US$991m |
| Dec 31 2019 | US$14m | US$1m | US$1b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$16m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$795m |
| Mar 31 2018 | n/a | n/a | US$840m |
| Dec 31 2017 | US$15m | US$1m | US$609m |
Rémunération vs marché: La rémunération totale de Joe ($USD 13.79M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Joe a augmenté alors que l'entreprise n'est pas rentable.
PDG
Joe Almeida (62 yo)
8.6yrs
Titularisation
US$13,786,671
Compensation
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board | 8.6yrs | US$13.79m | 0.11% $ 21.6m | |
| Executive VP & CFO | less than a year | US$5.37m | 0% $ 0 | |
| Executive VP & Group President of Medical Products and Therapies | 1.4yrs | US$4.86m | 0.031% $ 6.1m | |
| Executive VP & Group President of Pharmaceuticals | 2.1yrs | US$3.87m | 0.0016% $ 301.0k | |
| Executive VP & Group President of Kidney Care | 1.2yrs | US$9.64m | 0.0046% $ 881.8k | |
| Senior VP and Chief Medical & Scientific Officer | 1.6yrs | pas de données | pas de données | |
| Senior VP & Chief Information Officer | less than a year | pas de données | pas de données | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Executive VP & General Counsel | 2.3yrs | US$5.66m | 0.0018% $ 349.2k | |
| Senior Vice President | no data | pas de données | pas de données | |
| Executive VP & Chief Human Resources Officer | 7.3yrs | US$4.14m | 0.037% $ 7.1m | |
| Executive VP & Chief Supply Chain Officer | 4.6yrs | pas de données | 0.0030% $ 576.9k |
1.8yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BAX n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board | 8.6yrs | US$13.79m | 0.11% $ 21.6m | |
| Independent Director | less than a year | US$197.82k | 0.0018% $ 343.4k | |
| Chairman Emeritus | 8.6yrs | US$17.88m | pas de données | |
| Independent Director | 2.3yrs | US$349.64k | 0.0026% $ 501.7k | |
| Independent Director | 7.5yrs | US$373.98k | 0.0055% $ 1.1m | |
| Independent Director | 5.5yrs | US$364.98k | 0.0042% $ 808.5k | |
| Independent Director | 2.7yrs | US$363.00k | 0.0028% $ 540.3k | |
| Independent Director | 7.6yrs | US$367.31k | 0.0044% $ 852.8k | |
| Lead Independent Director | 2.3yrs | US$382.31k | 0.0026% $ 501.7k | |
| Independent Director | 3.5yrs | US$357.00k | 0.0032% $ 615.5k | |
| Independent Director | 1.2yrs | US$226.35k | 0.0019% $ 372.4k | |
| Independent Director | 5.5yrs | US$352.98k | pas de données |
4.5yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BAX sont considérés comme expérimentés (ancienneté moyenne 4.5 ans).